Maxigen Biotech Inc Asset Resilience Ratio
Maxigen Biotech Inc asset resilience ratio. Maxigen Biotech Inc (1783) has an Asset Resilience Ratio of 12.37% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can Maxigen Biotech Inc fund operations to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Maxigen Biotech Inc (2009–2025)
Asset resilience ratio of Maxigen Biotech Inc from 2009 to 2025. This chart shows how Maxigen Biotech Inc's Asset Resilience Ratio has changed over time. Read 1783 total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Maxigen Biotech Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Maxigen Biotech Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$251.50 Million | 12.37% |
| Total Liquid Assets | NT$251.50 Million | 12.37% |
Asset Resilience Insights
- Moderate Liquidity: Maxigen Biotech Inc has 12.37% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Maxigen Biotech Inc Industry Peers by Asset Resilience Ratio
Compare Maxigen Biotech Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Caina Technology Co. Ltd.
SHE:301122 |
Medical Instruments & Supplies | 19.55% |
|
Austco Healthcare Ltd
AU:AHC |
Medical Instruments & Supplies | 15.90% |
|
Nyxoah
BR:NYXH |
Medical Instruments & Supplies | 12.40% |
|
Ocumetics Technology Corp
V:OTC |
Medical Instruments & Supplies | 0.00% |
|
Osteopore Ltd
AU:OSX |
Medical Instruments & Supplies | 22.60% |
|
Ansell Ltd
AU:ANN |
Medical Instruments & Supplies | 7.53% |
|
Nanosonics Ltd
AU:NAN |
Medical Instruments & Supplies | 46.84% |
|
SDI Ltd
AU:SDI |
Medical Instruments & Supplies | 3.36% |
Maxigen Biotech Inc Asset Resilience Ratio by Year (2009–2025)
Maxigen Biotech Inc asset resilience ratio by year from 2009 to 2025. The table below shows the annual Asset Resilience Ratio data for Maxigen Biotech Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 15.93% | NT$301.50 Million ≈ $9.50 Million |
NT$1.89 Billion ≈ $59.64 Million |
+15.83pp |
| 2024-12-31 | 0.09% | NT$1.50 Million ≈ $47.26K |
NT$1.58 Billion ≈ $49.86 Million |
-0.01pp |
| 2023-12-31 | 0.10% | NT$1.50 Million ≈ $47.26K |
NT$1.49 Billion ≈ $47.04 Million |
-0.61pp |
| 2022-12-31 | 0.71% | NT$10.32 Million ≈ $325.01K |
NT$1.45 Billion ≈ $45.61 Million |
-1.41pp |
| 2021-12-31 | 2.12% | NT$26.87 Million ≈ $846.62K |
NT$1.27 Billion ≈ $39.86 Million |
+0.75pp |
| 2020-12-31 | 1.37% | NT$13.13 Million ≈ $413.82K |
NT$956.47 Million ≈ $30.13 Million |
-12.55pp |
| 2019-12-31 | 13.92% | NT$165.05 Million ≈ $5.20 Million |
NT$1.19 Billion ≈ $37.35 Million |
-6.53pp |
| 2018-12-31 | 20.45% | NT$232.25 Million ≈ $7.32 Million |
NT$1.14 Billion ≈ $35.77 Million |
+9.31pp |
| 2017-12-31 | 11.15% | NT$123.05 Million ≈ $3.88 Million |
NT$1.10 Billion ≈ $34.78 Million |
-12.37pp |
| 2016-12-31 | 23.52% | NT$258.07 Million ≈ $8.13 Million |
NT$1.10 Billion ≈ $34.57 Million |
+4.13pp |
| 2015-12-31 | 19.39% | NT$226.53 Million ≈ $7.14 Million |
NT$1.17 Billion ≈ $36.81 Million |
-23.56pp |
| 2014-12-31 | 42.95% | NT$435.41 Million ≈ $13.72 Million |
NT$1.01 Billion ≈ $31.94 Million |
+11.95pp |
| 2013-12-31 | 31.00% | NT$314.50 Million ≈ $9.91 Million |
NT$1.01 Billion ≈ $31.96 Million |
+23.83pp |
| 2012-12-31 | 7.17% | NT$36.26 Million ≈ $1.14 Million |
NT$505.76 Million ≈ $15.93 Million |
-4.97pp |
| 2011-12-31 | 12.14% | NT$59.09 Million ≈ $1.86 Million |
NT$486.65 Million ≈ $15.33 Million |
+11.95pp |
| 2010-12-31 | 0.19% | NT$820.00K ≈ $25.83K |
NT$429.76 Million ≈ $13.54 Million |
-0.93pp |
| 2009-12-31 | 1.12% | NT$3.85 Million ≈ $121.36K |
NT$343.55 Million ≈ $10.82 Million |
-- |
About Maxigen Biotech Inc
Maxigen Biotech Inc. researches, develops, produces, and sells implantable medical devices in Taiwan, America, Europe, rest of Asia, and internationally. It operates through two segments, Biomedical Products and Consumer Products. The company provides biomedical materials, such as collagen and bone supplements; beauty and skincare products; and medical devices for ophthalmology, otolaryngology, d… Read more